依达拉奉联合灯盏细辛治疗急性脑梗死临床观察

目的 观察依达拉奉联合灯盏细辛治疗急性脑梗死(ACI)的疗效及安全性.方法 采用随机、双盲对照,选择发病48h内的ACI患者64例,随机分为依达拉奉联合灯盏细辛(联合组)和灯盏细辛对照组.联合组予依达拉奉注射液30mg 生理盐水(NS)100ml静脉滴注2次/d,同时灯盏细辛注射30ml NS250ml静脉滴注1次/d,连续14d;对照组给予灯盏细辛30ml NS250ml静脉滴注1次/d,连续14d.两组均口服阿司匹林50-75mg/d.治疗前及治疗后第7d、第14d、第2ld分别进行欧洲卒中评分(ESS)、临床疗效评价及治疗前、治疗后第21d行血液流变学等实验室检查.结果 与对照组相比,第7d联合组ESS明显改善(p＜0.05),第14d、21d有极显著差异(均p＜0.001);联合组总有效率为93.8%,明显好于对照组(71.9%)(P＜0.05);两组血流变学治疗前后也有明显改善;两组各出现一例出血性脑梗死.结论 依达拉奉联合灯盏细辛治疗ACI安全、有效.

The study of clinical curative effect edaravone and erigeron breviscapus in treatment of acute cerebral infarction

Objective To observe the effect and safety of edaravone and erigeron breviscapus in treatment of acute cerebral infarction(ACI).Methods In this double blind random trial,64 patients in ACI that onseted in 48 hours were recruited randomly separated into two groups,the unite groups treated by edaravone and erigeron breviscapus,control groups treated by erigeron breviscapus only.The unite groups treated by edaravone injection 30mg into NS 100ml i.v.drip twice a day and erigeron breviscapus injection 30ml into NS 250ml i.v.drip once a day together for 14 days,the control groups treated by erigeron breviscapus injection 30ml into NS 250ml i.v.drip once a day only for 14 days.Two groups took aspirin 50-75mg/d too.Scored by ESS,estimated clinical curative effect at the 7th day,the 14th day and the 21st day prior treatment and post-treatment,and experimental examined on blood rheology at the 21st day.Results The unite groups had manif amelioration at the 7th day than control groups by ESS(p<0.05),and exceeding significant deviation at the 14th day,the 21st day(p<0.001).The unite groups total effective rate were 93.8%,better than control groups(71.9%)(p<0.05).The blood theology had manif amelioration in the both groups too.Both groups had one hemorrhagic cerebral infarction each other.Conclusions The edaravone and erigeron breviscapus in treatment of ACI is safety and utility.